Showing results (1-10 of 1,406) with videos related to
Sort By:
Pageof 141
Clinical Lung Cancer|April 28, 2006
Emerging antiangiogenic agents in lung cancerDavid Lee, John V HeymachJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignanciesPetros Nikolinakos, John V HeymachThe Oncologist|January 5, 2021
New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung CancerXiuning Le, John V HeymachClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2015
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?Tina Cascone, John V HeymachNature Reviews. Cancer|August 14, 2019
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapyFerdinandos Skoulidis, John V HeymachClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
The convergent development of molecular-targeted drugs for cancer treatment and preventionScott M Lippman, John V HeymachClinical Lung Cancer|March 27, 2007
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancerLauren A Byers, John V HeymachClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Farnesyl transferase inhibitors for patients with lung cancerBruce E Johnson, John V HeymachClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancerEmer O Hanrahan, John V HeymachCancer Cell|October 11, 2022
A STING operation to expose KRAS and STK11 co-mutated lung cancersFerdinandos Skoulidis, John V Heymach, Tina CasconePageof 141